MA-DECIPHERA
19.7.2024 02:01:34 CEST | Business Wire | Press release
Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib, a colony stimulating factor 1 receptor (CSF1R), for the treatment of patients with tenosynovial giant cell tumor (TGCT), which is under development by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly-owned subsidiary of Ono. The review of the MAA begins under the EMA’s centralized review process for all 27 member states of the European Union (EU), as well as Iceland, Liechtenstein and Norway. Vimseltinib was granted Orphan Drug Designation for the treatment of TGCT by the EMA in December 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717971793/en/
“Building upon positive results from the MOTION pivotal Phase 3 study, we are excited to initiate the regulatory review process in the EU and we are one step closer in our mission to bring vimseltinib to TGCT patients in need of an effective and well-tolerated treatment,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals.
The submission is supported by the data from the pivotal Phase 3 MOTION study, evaluating the efficacy and safety of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed), compared to placebo. In the study, vimseltinib demonstrated a statistically significant and clinically meaningful objective response rate (ORR) at Week 25 in the intent-to-treat (ITT) population, as assessed by Blinded Independent Radiologic Review (BIRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), versus placebo (40% in vimseltinib arm vs 0% in placebo arm, p <0.0001). Additionally, vimseltinib demonstrated statistically significant and clinically meaningful improvements versus placebo in all key secondary endpoints. The safety profile of vimseltinib is manageable and safety data from MOTION are consistent with data previously disclosed in the Phase 1/2 clinical trial of vimseltinib*. Data from the MOTION study was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
*: Gelberblom, et at. 2024 ASCO Annual Meeting
About the MOTION Study
The MOTION study is a two-part, randomized, double-blind, placebo-controlled Phase 3 clinical study to assess the efficacy and safety of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed). The primary endpoint of the study is an objective response rate (ORR) at Week 25 in the intent-to-treat (ITT) population, as assessed by Blinded Independent Radiologic Review (BIRR) per using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), versus placebo. The secondary endpoint includes ORR per tumor volume score (TVS), active range of motion (ROM), physical function, stiffness, quality of life, and pain, all assessed at Week 25. This study consists of two Parts. In Part 1, patients were randomized to receive either vimseltinib or placebo for 24 weeks. In Part 2, patients randomized to placebo in Part 1 have the option to receive vimseltinib, and all patients receive vimseltinib for a long-term period in an open-label setting.
About Tenosynovial Giant Cell Tumor (TGCT)
TGCT is a rare disease caused by a translocation in colony-stimulating factor 1 (CSF1) gene resulting in overexpression of CSF1 and recruitment of colony-stimulating factor 1 receptor (CSF1R)-positive inflammatory cells into the lesion. TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), a diffuse-type of TGCT. Although benign, these tumors can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint. Surgery is the main treatment option; however, these tumors tend to recur, particularly in diffuse-type TGCT. If untreated or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability. For a subset of patients who are not amenable to surgery, systemic treatment options are limited and a new therapeutic option for TGCT is needed.
About Vimseltinib
Vimseltinib is an investigational, oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R. Vimseltinib has been developed using Deciphera’s proprietary switch-control kinase inhibitor platform.
About Deciphera Pharmaceuticals Inc.
(As of June 11, 2024, Deciphera is now a member of ONO Pharma.)
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor approved for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is approved in many countries including the European Union and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717971793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in MSI-High Solid Tumors10.11.2026 13:00:00 CET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System designed to identify patients with microsatellite high (MSI-H) solid tumors as a companion diagnostic designed for KEYTRUDA®, Merck’s (known as MSD outside the U.S. and Canada) anti-PD-1 therapy. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in solid tumor tissue. MSI status can be used to inform treatment decisions and support precision oncology strategies. “This approval reflects our dedication to providing meaningful diagnostic advances, developed to the highest quality and regulatory standards,” says Alok Sharma, Global Clinical Market Director at Promega. “Our test connects patients with the therapy most likely to help them, working alongside our pharmaceutical collaborators and the clinicians who use the result.” This approval was supported through a collaboration with Merck, which markets KEYTRUDA®. Together, the companies are working to a
Component Sense Celebrates 25 Years With Over 80 Million Electronic Components Saved From Landfill10.11.2026 13:00:00 CET | Press release
Global electronics redistribution company marks its anniversary by planting 2,500 trees Component Sense, a global company specialising in the redistribution of excess and obsolete electronic components, has now saved over 80 million components from landfill. The milestone coincides with its 25th anniversary this November, which it is marking by planting 2,500 trees with One Tree Planted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110298637/en/ Kenny McGee, CEO and Founder, Component Sense The company redistributes excess components from Tier 1 original equipment manufacturers (OEMs) and electronics manufacturing services (EMS) providers to a global network of buyers, helping manufacturers recoup value from inventory that would otherwise go to waste. Excess inventory is both a financial and an environmental burden for electronics manufacturers. With lead times still running long, shortages and surpluses exist side by s
Suzano Publishes First Report Aligned With Taskforce on Nature-related Financial Disclosures Recommendations10.11.2026 12:18:00 CET | Press release
Report offers insight on Suzano’s ecosystem health impacts, risks and opportunities, and reinforces its nature strategy Suzano, the world’s largest pulp producer, has published its first report aligned with the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD). The TNFD reporting framework helps organizations identify and assess how their dependencies and impacts may generate nature and biodiversity related risks and opportunities, and to disclose how they are integrated into the company’s governance, strategy, and corporate management. Initially focused on Suzano’s direct Brazilian operations, the report establishes methodological foundations, strengthens internal capabilities, and creates a pathway for the gradual expansion of nature-related assessments and disclosures over the coming years. The report also reinforces Suzano’s Nature Strategy, launched in November 2025. As part of its ongoing commitment to stronger management and greater transparency reg
Robbyant Releases LingBot-Touch to Bring General-Purpose Touch Perception to Robots10.11.2026 10:23:00 CET | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-Touch, a tactile foundation model that gives robots a critical missing sense by enabling robust touch perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109284905/en/ LingBot-Touch encodes magnetic tactile, visual tactile, and piezoresistive signals into unified tactile tokens for use by different action models. Pre-trained on nearly 5,000 hours of real-world tactile data, the model covers three mainstream sensing modalities—magnetic tactile, visual tactile, and piezoresistive sensing—and translates their diverse signals into a unified tactile representation. This allows different dexterous hands and action models to share and reuse tactile understanding, enabling robots to not only “see clearer” and “think deeper,” but also “feel sharper” during fine manipulation tasks, such as turning pages, unscrewing bottle ca
Wise Selects Navan to Modernize Global Travel Program10.11.2026 10:00:00 CET | Press release
Global financial technology company plans to improve traveler choice, cost control and visibility Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Wise (Nasdaq:WSE, LSE:WISE), the global financial technology company building the best way to move and manage the world's money, has selected Navan to manage its business travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109603155/en/ Global financial technology company plans to improve traveler choice, cost control and visibility “Our teams travel across the world to work together and support our customers, so it's important that booking and managing travel is straightforward,” said Hanro Hennig, VP Global Real Estate, Workplace and Risk at Wise. “We're working with Navan to make that experience simpler, while giving us better visibility and control over travel costs.” Key anticipated benefits of the partnershi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom